This $303,024 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of Biocognon LLC's innovative combinatorial pipeline for discovering anti-GPCR nanobodies.
The key objectives are to: 1) develop a robust system for assembling GPCR/nanobody libraries, 2) build a synthetic nanobody library against the ADRB1 and ADRB2 GPCRs and screen for therapeutic candidates, and 3) implement a combinatorial screen across four GPCR targets to demonstrate the full functionality of Biocognon's nanobody discovery platform. If successful, this work is expected to enable more effective targeting of the 400 druggable human non-olfactory GPCRs, a high-value class of therapeutic targets representing 30% of current medicines.
Generated 3/4/25, 4:57 AM